Top 15 Cancer Stories of 2015

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

The phase 3 NIVOPOSTOP GORTEC 2018-01 trial shows that nivolumab added to radiotherapy and cisplatin had improved efficacy over SOC treatments in SCCHN.

Efficacy findings from a phase 2 trial demonstrated that abenacianine visualized lung tumor tissue and was well tolerated when used during surgery.